Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED Phase 2

A Study to Evaluate EDP 938 Regimens in Children With RSV

NCT04816721 · View on ClinicalTrials.gov ↗

Study Summary

A 2-part study to evaluate the safety, pharmacokinetics and efficacy of EDP-938 in children with RSV infection.

Interventions

  • DRUG Placebo
  • DRUG EDP-938

Study Locations (20)

California

  • Memorial Care Miller Children's and Women's Hospital — Long Beach
  • University of California Los Angeles (UCLA) — Los Angeles
  • University of California Davis — Sacramento

Louisiana

  • MedPharmics - Lafayette — Lafayette
  • LSU Health — Shreveport
  • Willis-Knighton Health System — Shreveport

Other

  • Hospital Interzonal Dr Jose Penna — Bahía Blanca
  • Clínica Privada del Sol — Buenos Aires
  • Instituto Medico Rio Cuarto — Río Cuarto

Florida

  • Nemours Children's Hospital — Orlando
  • South Tampa Center for Advanced Healthcare — Tampa

Texas

  • Driscoll Children's Hospital — Corpus Christi
  • Children's Health Specialty Center Dallas Campus — Dallas

Idaho

  • Rexburg Pediatrics — Rexburg

Illinois

  • Ann & Robert H. Lurie Children's Hospital of Chicago — Chicago

Kentucky

  • Norton Children's Research Institute — Louisville

Trial Details

FieldValue
Enrollment Target 99 participants
Start Date 2022-04-26
Est. Completion 2024-08-19
Phase Phase 2

Sponsor

Enanta Pharmaceuticals

9 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04816721

The ClinicalTrials.gov registry entry for NCT04816721 describes a study currently listed as completed. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 99 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Enanta Pharmaceuticals, which has 9 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Respiratory Syncytial Virus (RSV) appearing as the primary indexed condition, and to 2 interventions — of which Placebo is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT04816721 reports 20 study locations spanning 12 distinct geographic areas — top geographies include California, Louisiana, Other. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT04816721 about?

NCT04816721 is a clinical study titled "A Study to Evaluate EDP 938 Regimens in Children With RSV". A 2-part study to evaluate the safety, pharmacokinetics and efficacy of EDP-938 in children with RSV infection.

What is the current status of trial NCT04816721?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 99 participants. The study started on 2022-04-26. Estimated completion is 2024-08-19.

What conditions does trial NCT04816721 study?

This clinical trial studies the following conditions: Respiratory Syncytial Virus (RSV). These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT04816721?

The interventions under investigation include: Placebo (DRUG), EDP-938 (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT04816721?

This trial is sponsored by Enanta Pharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT04816721 being conducted?

This trial has 20 study locations across California, Florida, Idaho, Illinois, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial